Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GCK | P35557 | 1/20 | 0.31 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.30 |
| ▸ | GRM5 | P41594 | 1/20 | 0.30 |
| ▸ | WEE1 | P30291 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10468432 | 0.85 | MEN1 (0.33) | MEN1KMT2AKDM4CGRM5WEE1 | |
| SCHEMBL10576592 | 0.83 | MEN1 (0.38) | MEN1KMT2AGCKKDM4CGRM5 | |
| SCHEMBL5857211 | 0.83 | MEN1 (0.34) | MEN1KMT2AKDM4CGRM5WEE1 | |
| SCHEMBL6151292 | 0.83 | MEN1 (0.36) | MEN1KMT2AKDM4CGRM5WEE1 | |
| SCHEMBL10736966 | 0.82 | WEE1 (0.32) | MEN1KMT2AGCKWEE1 | |
| SCHEMBL31252992 | 0.82 | MEN1 (0.32) | MEN1KMT2AGCKWEE1 | |
| SCHEMBL11143492 | 0.82 | MEN1 (0.36) | MEN1KMT2AKDM4CGRM5WEE1 | |
| SCHEMBL21641751 | 0.82 | MEN1 (0.36) | MEN1KMT2AKDM4CGRM5WEE1 | |
| SCHEMBL7881560 | 0.82 | MEN1 (0.33) | MEN1KMT2AKDM4CGRM5WEE1 | |
| SCHEMBL11714601 | 0.81 | MEN1 (0.32) | MEN1KMT2AGCKWEE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024114782-A1 | SMALL-MOLECULE MODULATORS OF SPIKE PROTEIN | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2024-06-06 | — | — | WO | disclosed |
| US-20080045596-A1 | Ep2 Receptor Agonists | ASTERAND, INC. | 2008-02-21 | — | — | US | disclosed |
| EP-1334095-B1 | PROCESS FOR THE PREPARATION OF PGD2 ANTAGONIST | SHIONOGI & CO (JP) | 2005-01-19 | — | — | EP | disclosed |
| EP-1334095-A4 | PROCESS FOR THE PREPARATION OF PGD2 ANTAGONIST | SHIONOGI & CO (JP) | 2004-03-17 | — | — | EP | disclosed |
| US-6693203-B2 | REACTING NOPINONE ENOLATE WITH ALKYL 7-HALO-5-HEPTYNOATE, REACTING PRODUCT WITH HYDROXYLAMINE, TREATING WITH TITANIUM TRICHLORIDE AND BORANE REAGENT, HYDROGENATING, REACTING WITH 5-HYDROXY-4-BENZOTHIOPHENECARBOXYLIC ACID, HYDROLYZING | SHIONOGI & CO., LTD (JP) | 2004-02-17 | — | — | US | disclosed |
| US-20030199702-A1 | Process for the preparation of pgd2 antagonist | LARSEN ROBERT (US) | 2003-10-23 | — | — | US | disclosed |
| EP-1334095-A1 | PROCESS FOR THE PREPARATION OF PGD2 ANTAGONIST | SHIONOGI & CO., LTD. (JP) | 2003-08-13 | — | — | EP | disclosed |
| WO-2002032892-A1 | PROCESS FOR THE PREPARATION OF PGD2 ANTAGONIST | SHIONOGI & CO., LTD (JP) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199702-A1 | Process for the preparation of pgd2 antagonist | PTGDR, PTGDR2, PTGER2 | MEN1 4673/4885KMT2A 2186/4885GCK 2037/4885 |
| US-20080045596-A1 | Ep2 Receptor Agonists | PTGER2, PTGER1, PTGER3 | MEN1 4210/4885KMT2A 2044/4885GCK 3562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.